Astra seeks U.S. okay for Seroquel XR in anxiety
LONDON, May 8 (Reuters) - AstraZeneca Plc (AZN.L: Quote, Profile, Research) said on Thursday it had applied to U.S. regulators to sell its schizophrenia drug Seroquel XR as a treatment for anxiety.
If approved, Seroquel XR would be the first atypical antipsychotic medicine cleared for the treatment of generalised anxiety disorder.
Seroquel XR -- a follow-on extended release version of AstraZeneca's older $4 billion-a-year seller Seroquel -- was approved in the United States for schizophrenia in 2007. AstraZeneca is also seeking clearance to sell the new drug for bipolar disorder. (Reporting by Ben Hirschler)
© Thomson Reuters 2009 All rights reserved
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India. Full Coverage
PLAYBOY SALE
An icon bows to changing times
With his Playboy Enterprises in talks to be sold for about $300 million, the 83 year-old Hugh Hefner will be giving up control over the iconic adult entertainment empire he founded that was instrumental in shaping society's opinions on nudity, sex and free speech. Full Article
India
US
UK
